FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116323453> ?p ?o ?g. }

• W2116323453 endingPage "13" @default.
• W2116323453 startingPage "1203" @default.
• W2116323453 abstract "Our purpose was to determine the maximum tolerated dose and toxicity associated with soluble Chinese hamster ovary [s(CHO)] recombinant human interleukin (IL) 1 receptor (IL-1R; Immunex, Seattle, WA) administration in humans and to determine the effective biological dose and/or maximum tolerated dose of the s(CHO) IL-1R in combination with high-dose IL-2 as determined by reduction in IL-2 toxicity and modulation of its biological effects. Twenty-seven patients with metastatic cancer were treated with escalating doses of s(CHO) IL-1R at 1, 1, 5, 10, 20, 40, and 55 mg/m2 i.v. on days -6 (except cohort 2), 1, and 15 and IL-2 at doses of 300,000 IU/kg (cohort 1) and 600,000 IU/kg (cohorts 2-7) i.v. every 8 h on days 1-5 and 15-19. No toxicity directly attributable to s(CHO) IL-1R was observed. The median number of IL-2 doses was 23. Hypotension and neurotoxicity were the major dose-limiting toxicities for the IL-2/s(CHO) IL-1R combination. Of the 24 patients treated with full-dose IL-2, there were six responses, three complete and three partial (response rate, 25%). Three patients developed thyroid dysfunction, and all 3 responding melanoma patients exhibited vitiligo. The t1/2 of s(CHO) IL-1R alone was 24-30 h and was not significantly altered by coadministration with IL-2. Whole-blood functional assays indicated that sufficient s(CHO) IL-1R was present in the circulation at top dose levels to inhibit the in vitro effects of IL-1beta on IL-8 induction; however, no effect on IL-2-induced IL-8 induction, or on the IL-1beta- or IL-2-induced tumor necrosis factor production, was observed. Suppression of IL-2-mediated tumor necrosis factor alpha and IL-6 induction in vivo during the first 24 h after IL-2 administration was observed, and the neutrophil chemotactic defect normally seen with IL-2 was not observed. IL-1R antagonist induction far exceeded that seen previously with IL-2 alone. No inhibition of either serum C-reactive protein induction or enhanced urinary nitrate excretion and no consistent effect on IL-2-related changes in peripheral blood mononuclear cell phenotype or endothelial adhesion molecule expression were seen. The coadministration of s(CHO) IL-1R produced no apparent reduction in IL-2 clinical toxicity manifested by either the ability to administer more IL-2 than anticipated or a reduction in the toxicity associated with a given amount of IL-2. Therefore, no effective biological dose could be identified for the s(CHO) IL-1R." @default.
• W2116323453 created "2016-06-24" @default.
• W2116323453 creator A5007052233 @default.
• W2116323453 creator A5010538976 @default.
• W2116323453 creator A5017058881 @default.
• W2116323453 creator A5023383165 @default.
• W2116323453 creator A5037823982 @default.
• W2116323453 creator A5039373037 @default.
• W2116323453 creator A5052526230 @default.
• W2116323453 creator A5053486627 @default.
• W2116323453 creator A5065282550 @default.
• W2116323453 creator A5066250381 @default.
• W2116323453 date "1998-05-01" @default.
• W2116323453 modified "2023-09-27" @default.
• W2116323453 title "A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor." @default.
• W2116323453 cites W110661968 @default.
• W2116323453 cites W1487282140 @default.
• W2116323453 cites W1487984429 @default.
• W2116323453 cites W1515175043 @default.
• W2116323453 cites W1585911998 @default.
• W2116323453 cites W1771243425 @default.
• W2116323453 cites W1843453924 @default.
• W2116323453 cites W1894837930 @default.
• W2116323453 cites W1904436785 @default.
• W2116323453 cites W1951540415 @default.
• W2116323453 cites W1964032970 @default.
• W2116323453 cites W1968795960 @default.
• W2116323453 cites W1990237417 @default.
• W2116323453 cites W1999701898 @default.
• W2116323453 cites W204546040 @default.
• W2116323453 cites W2058066653 @default.
• W2116323453 cites W2096428903 @default.
• W2116323453 cites W2098074625 @default.
• W2116323453 cites W2120872446 @default.
• W2116323453 cites W2130537353 @default.
• W2116323453 cites W2131632510 @default.
• W2116323453 cites W2133988080 @default.
• W2116323453 cites W2149724818 @default.
• W2116323453 cites W2167447755 @default.
• W2116323453 cites W2171561094 @default.
• W2116323453 cites W2178727026 @default.
• W2116323453 cites W2242340339 @default.
• W2116323453 cites W2267316137 @default.
• W2116323453 cites W2319915844 @default.
• W2116323453 cites W2336865510 @default.
• W2116323453 cites W2416128450 @default.
• W2116323453 cites W2462814829 @default.
• W2116323453 cites W336652537 @default.
• W2116323453 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9607578" @default.
• W2116323453 hasPublicationYear "1998" @default.
• W2116323453 type Work @default.
• W2116323453 sameAs 2116323453 @default.
• W2116323453 citedByCount "3" @default.
• W2116323453 countsByYear W21163234532022 @default.
• W2116323453 crossrefType "journal-article" @default.
• W2116323453 hasAuthorship W2116323453A5007052233 @default.
• W2116323453 hasAuthorship W2116323453A5010538976 @default.
• W2116323453 hasAuthorship W2116323453A5017058881 @default.
• W2116323453 hasAuthorship W2116323453A5023383165 @default.
• W2116323453 hasAuthorship W2116323453A5037823982 @default.
• W2116323453 hasAuthorship W2116323453A5039373037 @default.
• W2116323453 hasAuthorship W2116323453A5052526230 @default.
• W2116323453 hasAuthorship W2116323453A5053486627 @default.
• W2116323453 hasAuthorship W2116323453A5065282550 @default.
• W2116323453 hasAuthorship W2116323453A5066250381 @default.
• W2116323453 hasConcept C126322002 @default.
• W2116323453 hasConcept C134018914 @default.
• W2116323453 hasConcept C170493617 @default.
• W2116323453 hasConcept C175656101 @default.
• W2116323453 hasConcept C2777371288 @default.
• W2116323453 hasConcept C2778690821 @default.
• W2116323453 hasConcept C29730261 @default.
• W2116323453 hasConcept C71924100 @default.
• W2116323453 hasConcept C74172505 @default.
• W2116323453 hasConcept C90924648 @default.
• W2116323453 hasConcept C98274493 @default.
• W2116323453 hasConceptScore W2116323453C126322002 @default.
• W2116323453 hasConceptScore W2116323453C134018914 @default.
• W2116323453 hasConceptScore W2116323453C170493617 @default.
• W2116323453 hasConceptScore W2116323453C175656101 @default.
• W2116323453 hasConceptScore W2116323453C2777371288 @default.
• W2116323453 hasConceptScore W2116323453C2778690821 @default.
• W2116323453 hasConceptScore W2116323453C29730261 @default.
• W2116323453 hasConceptScore W2116323453C71924100 @default.
• W2116323453 hasConceptScore W2116323453C74172505 @default.
• W2116323453 hasConceptScore W2116323453C90924648 @default.
• W2116323453 hasConceptScore W2116323453C98274493 @default.
• W2116323453 hasIssue "5" @default.
• W2116323453 hasLocation W21163234531 @default.
• W2116323453 hasOpenAccess W2116323453 @default.
• W2116323453 hasPrimaryLocation W21163234531 @default.
• W2116323453 hasRelatedWork W1986592065 @default.
• W2116323453 hasRelatedWork W2017793865 @default.
• W2116323453 hasRelatedWork W2029027714 @default.
• W2116323453 hasRelatedWork W2034236312 @default.
• W2116323453 hasRelatedWork W2038163560 @default.
• W2116323453 hasRelatedWork W2038220228 @default.
• W2116323453 hasRelatedWork W2062321041 @default.

• next